A5102957443- Cancer Immunotherapy and Biomarkers
- Gut microbiota and health
- Cancer, Stress, Anesthesia, and Immune Response
- Colorectal Cancer Treatments and Studies
- Virus-based gene therapy research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Immune cells in cancer
- Kawasaki Disease and Coronary Complications
- Neonatal and Maternal Infections
- Hepatocellular Carcinoma Treatment and Prognosis
- Single-cell and spatial transcriptomics
- Monoclonal and Polyclonal Antibodies Research
- Genetic factors in colorectal cancer
- Bladder and Urothelial Cancer Treatments
- Pediatric Hepatobiliary Diseases and Treatments
- IgG4-Related and Inflammatory Diseases
- Cholangiocarcinoma and Gallbladder Cancer Studies
- IL-33, ST2, and ILC Pathways
- Liver Disease Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
Xuzhou Medical College
2025
Xuzhou Central Hospital
2025
First Affiliated Hospital Zhejiang University
2019-2024
Zhejiang University
2018-2024
Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting response to anti-PD-1 HCC are still unclear. Herein, we report dynamic variation characteristics specificities of gut microbiome during using metagenomic sequencing.Fecal samples from patients responding showed higher taxa richness more gene counts than those non-responders. For analysis...
The early diagnosis of hepatocellular carcinoma (HCC) can greatly improve patients' 5-year survival rate, and the efficacy assessment is important for oncologists to harness anti-programmed cell death protein 1 (PD-1) immunotherapy in patients with advanced HCC. lack effective predicting biomarkers not only leads delayed detection disease but also results ineffective limited clinical benefit.We exploited single-cell approach (cytometry by time flight (CyTOF)) analyze peripheral blood...
The majority of advanced biliary tract cancer (ABTC) patients will progress after gemcitabine and cisplatin (GP) doublet therapy, while the standard second-line regimen has not been established. We conducted this study to assess efficacy safety irinotecan capecitabine (XELIRI) vs. monotherapy in ABTC progressed on GP.Sixty-four GP refractory were randomised either 180 mg/m2 day 1 plus 1000 twice daily days 1-10 a 14-day cycle (XELIRI-arm) or single-agent (IRI-arm). Treatments repeated until...
Abstract Background The paucity of reliable biomarkers for predicting immunotherapy efficacy in patients with advanced hepatocellular carcinoma (HCC) has emerged as a burgeoning concern the expanding use immunotherapy. This study endeavors to delve into potential peripheral capable prognosticating HCC who are poised receive anti-PD-1 monotherapy within phase III clinical trial, KEYNOTE394. Additionally, we sought elucidate underlying molecular mechanisms resistance immune checkpoint blockade...
Kawasaki disease (KD) is an acute febrile vasculitis and the leading cause of acquired heart in children. However, early diagnosis KD remains challenging, its pathogenic mechanisms are yet to be fully elucidated. This study utilized Olink Targeted Proteomics analyze serum protein profiles identify potential diagnostic biomarkers for patients with KD. Based on children final diagnosis, they were categorized into either group or control (FC) group. Serum samples from each randomly selected...
Immune checkpoint blockade with monoclonal antibodies (mAbs) that target programmed cell death protein-1 (PD-1) has remarkably revolutionized cancer therapy. Their binding kinetics measured by surface plasmon resonance does not always correlate well their immunotherapeutic efficacies, mainly due to the lack of two-dimensional plasma membrane and capability force sensing manipulation. In this regard, based on a more suitable ultra-sensitive biomechanical nanotool, biomembrane probe (BFP), we...
Colorectal cancer (CRC) is known to be resistant immunotherapy. In our phase-I clinical trial, one patient achieved a 313-day prolonged response during the combined treatment of oncolytic virotherapy and To gain deeper understanding potential molecular mechanisms, we performed comprehensive multi-omics analysis on this three non-responders. Our investigation unveiled that, initially, tumor microenvironment (TME) responder presented minimal infiltration T cells natural killer cells, along...
Cetuximab is used for colorectal cancer (CRC) treatment. However, the early biomarker of treatment efficacy cetuximab has not been identified.After 1 year treatment, patients were divided into an effective group and ineffective group. The interleukin-33 (IL-33) level distribution lymphatic cells in investigated by analyzing peripheral blood mononuclear via flow cytometry analysis ELISA. correlation between IL-33 immunomodulatory effect was determined through experiments vivo vitro.The...
<h3>Background</h3> In recent years, the role of inflammatory microenvironment induced by gut microbiome in occurrence and development CRC has received increased attention across a number disciplines. WLS is probiotics product consisted with 6 billion live probiotics, mainly Lactobacillus helveticus Bifidobacterium longum. To further explore influence anti-tumor efficacy patients mCRC, we conducted randomized controlled trial (NCT04021589). <h3>Methods</h3> Patients receiving corresponding...